The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ips-339     1-(fluoren-9- ylideneamino)oxy-3-(tert...

Synonyms: IPS 339, AC1L3TIG, AR-1H5680, LS-177379, AC1Q3F4D, ...
This record was replaced with 121848.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Psychiatry related information on 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol

  • Intrathecally administered propranolol (1 and 5 micrograms per rat), atenolol (1 and 5 micrograms per rat) and IPS-339 (1 and 5 micrograms per rat) remarkably inhibited the increase of the response latency induced by MA (50 ng per rat) given into the NRPG [1].

High impact information on 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol

  • Atenolol (1 mg/kg) attenuated significantly the decrease in myocardial pH that had been induced by partial occlusion, whereas IPS 339 (360 micrograms/kg) and ICI 118,551 (300 micrograms/kg) did not [2].
  • Isoproterenol elicited a significant renin release in the presence of beta-1 adrenoceptor blockade with atenolol and in the presence of selective beta-2 adrenoceptor blockade with IPS-339 [3].
  • 2 The present experiments examine the effects of a potent and highly specific beta 2-antagonist (IPS 339) on intraocular pressure in the normal rabbit eye [4].
  • Practolol and CGP 20712A (selective beta 1-adrenoceptor antagonists) displaced with high affinity from a greater proportion of sites than ICI 118,551 and IPS 339 (selective beta 2-adrenoceptor antagonists) [5].
  • Studies with a specific beta 2-antagonist, IPS 339, indicated that 72% of receptors present were of the beta 2-subtype [6].

Biological context of 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol


Anatomical context of 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol


Associations of 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol with other chemical compounds

  • Propranolol, 2.5 mg/kg intraperitoneally, and the selective beta 2-receptor antagonist IPS 339, 5 mg/kg intraperitoneally, almost completely antagonized the effect of clenbuterol, 1 mg/kg intraperitoneally [12].

Gene context of 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol

  • IPS 339, a selective antagonist of beta-2 adrenoceptors, also injected icv, reduced PRL secretion during stress in a dose dependent fashion [13].

Analytical, diagnostic and therapeutic context of 1-(fluoren-9-ylideneamino)oxy-3-(tert-butylamino)propan-2-ol

  • Intravenous injection of IPS-339 (0.03, 0.1 and 0.3 mg/kg), a selective beta-2 adrenoceptor antagonist, diminished the stimulation-induced increases in LV dp/dt max and coronary sinus blood flow in a dose-dependent manner, whereas it did not decrease the stimulation-induced increase in NE output [14].


  1. Mechanism of the antinociceptive action of mesaconitine: participation of brain stem and lumbar enlargement. Hikino, H., Murayama, M. Br. J. Pharmacol. (1985) [Pubmed]
  2. Attenuation by atenolol of myocardial acidosis during ischemia in dogs: contribution of beta-1 adrenoceptors to myocardial acidosis. Sakai, K., Abiko, Y. J. Pharmacol. Exp. Ther. (1985) [Pubmed]
  3. Beta adrenergically mediated release of renin in the dog is not confined to either beta-1 or beta-2 adrenoceptors. Olson, R.D., Nies, A.S., Gerber, J.G. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  4. Effects of a potent and specific beta 2-adrenoceptor antagonist on intraocular pressure. Nathanson, J.A. Br. J. Pharmacol. (1981) [Pubmed]
  5. Beta-adrenoceptors in human brain labelled with [3H]dihydroalprenolol and [3H]CGP 12177. De Paermentier, F., Cheetham, S.C., Crompton, M.R., Horton, R.W. Eur. J. Pharmacol. (1989) [Pubmed]
  6. Failure to demonstrate decreased beta-adrenergic receptor concentration or decreased agonist efficacy in term or preterm human parturition. Dattel, B.J., Lam, F., Roberts, J.M. Am. J. Obstet. Gynecol. (1986) [Pubmed]
  7. Regional myocardial tissue blood flow during beta-adrenergic blockade in cat hearts with acute ischaemia. Stangeland, L., Grong, K., Lekven, J. Clinical physiology (Oxford, England) (1984) [Pubmed]
  8. Regional myocardial tissue blood flow during sequential beta 1- and beta 2-adrenergic blockade in cat hearts with acute ischaemia. Grong, K., Stangeland, L., Lekven, J. Scand. J. Clin. Lab. Invest. (1983) [Pubmed]
  9. beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol. Mattsson, H., Andersson, T., Carlsson, E., Hedberg, A., Lundgren, B., Olsson, T. Naunyn Schmiedebergs Arch. Pharmacol. (1982) [Pubmed]
  10. How beta2-selective is the adrenoceptor antagonist drug, IPS 339? O'Donnell, S.R., Walduck, K. J. Pharm. Pharmacol. (1981) [Pubmed]
  11. The adrenoceptor blocking properties of the new beta 2-selective antagonist, IPS 339 on tracheal smooth muscle and on slow contracting skeletal muscle. Holmberg, E., Jeppsson, A.B., Lamm, C.J., Waldeck, B. Acta pharmacologica et toxicologica. (1980) [Pubmed]
  12. Antagonism of reserpine-induced hypothermia in mice by some beta-adrenoceptor agonists. Ross, S.B. Acta pharmacologica et toxicologica. (1980) [Pubmed]
  13. Role of central beta-adrenoceptors on stress-induced prolactin release in rats. Haanwinckel, M.A., Antunes-Rodrigues, J., De Castro e Silva, E. Horm. Metab. Res. (1991) [Pubmed]
  14. Effects of epinephrine, isoproterenol and IPS-339 on sympathetic transmission to the dog heart: evidence against the facilitatory role of presynaptic beta adrenoceptors. Yorikane, R., Kanda, A., Kimura, T., Satoh, S. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
WikiGenes - Universities